These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 16651447)
1. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cohen AD; Diab A; Perales MA; Wolchok JD; Rizzuto G; Merghoub T; Huggins D; Liu C; Turk MJ; Restifo NP; Sakaguchi S; Houghton AN Cancer Res; 2006 May; 66(9):4904-12. PubMed ID: 16651447 [TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. Ramirez-Montagut T; Chow A; Hirschhorn-Cymerman D; Terwey TH; Kochman AA; Lu S; Miles RC; Sakaguchi S; Houghton AN; van den Brink MR J Immunol; 2006 Jun; 176(11):6434-42. PubMed ID: 16709800 [TBL] [Abstract][Full Text] [Related]
3. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651 [TBL] [Abstract][Full Text] [Related]
4. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849 [TBL] [Abstract][Full Text] [Related]
5. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169 [TBL] [Abstract][Full Text] [Related]
6. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. Zhou P; L'italien L; Hodges D; Schebye XM J Immunol; 2007 Dec; 179(11):7365-75. PubMed ID: 18025180 [TBL] [Abstract][Full Text] [Related]
7. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070 [TBL] [Abstract][Full Text] [Related]
8. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody. Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058 [TBL] [Abstract][Full Text] [Related]
9. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656 [TBL] [Abstract][Full Text] [Related]
10. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491 [TBL] [Abstract][Full Text] [Related]
11. In vivo ligation of glucocorticoid-induced TNF receptor enhances the T-cell immunity to herpes simplex virus type 1. La S; Kim E; Kwon B Exp Mol Med; 2005 Jun; 37(3):193-8. PubMed ID: 16000873 [TBL] [Abstract][Full Text] [Related]
12. Conversion of alloantigen-specific CD8+ T cell anergy to CD8+ T cell priming through in vivo ligation of glucocorticoid-induced TNF receptor. Kim J; Choi WS; Kang H; Kim HJ; Suh JH; Sakaguchi S; Kwon B J Immunol; 2006 May; 176(9):5223-31. PubMed ID: 16621987 [TBL] [Abstract][Full Text] [Related]
13. Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity. Cho JS; Hsu JV; Morrison SL Cancer Immunol Immunother; 2009 Jul; 58(7):1057-69. PubMed ID: 19018533 [TBL] [Abstract][Full Text] [Related]
14. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Boczkowski D; Lee J; Pruitt S; Nair S Cancer Gene Ther; 2009 Dec; 16(12):900-11. PubMed ID: 19498460 [TBL] [Abstract][Full Text] [Related]
15. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Hawkins WG; Gold JS; Dyall R; Wolchok JD; Hoos A; Bowne WB; Srinivasan R; Houghton AN; Lewis JJ Surgery; 2000 Aug; 128(2):273-80. PubMed ID: 10923004 [TBL] [Abstract][Full Text] [Related]
16. CD8 blockade promotes the expansion of antigen-specific CD4+ FOXP3+ regulatory T cells in vivo. Wang Z; Davies JD Int Immunopharmacol; 2007 Feb; 7(2):249-65. PubMed ID: 17178393 [TBL] [Abstract][Full Text] [Related]
17. Regulation of murine inflammatory bowel disease by CD25+ and CD25- CD4+ glucocorticoid-induced TNF receptor family-related gene+ regulatory T cells. Uraushihara K; Kanai T; Ko K; Totsuka T; Makita S; Iiyama R; Nakamura T; Watanabe M J Immunol; 2003 Jul; 171(2):708-16. PubMed ID: 12847237 [TBL] [Abstract][Full Text] [Related]
18. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
19. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483 [TBL] [Abstract][Full Text] [Related]